Shots:

• Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer- particularly NSCLC
• The joint research will continue for 5 additional years. The extended collaboration follows successful preclinical studies in GI cancers via joint VRDC
• The expanded agreement allows the partners to expand their lung cancer indication programs targeting KRAS and TRAILR2- including Boehringer Ingelheim’s BI 1701963- BI 1823911- BI 3011441- along with bi-specific TRAILR2 agonist

  Ref: Business Wire | Image: Twitter